SPAK dependent regulation of peptide transporters PEPT1 and PEPT2

Kidney and Blood Pressure Research

Volumn 39, Issue 4, 2014, Pages 388-398

  Warsi, Jamshed ^a   Dong, Luo ^a   Elvira, Bernat ^a   Salker, Madhuri S ^a   Shumilina, Ekaterina ^a   Hosseinzadeh, Zohreh ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cell volume; Intestine; Knockout mice; Peptide transport

Indexed keywords

BREFELDIN A; GLYCINE; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; PROTEIN KINASE; PROTEIN KINASE WNK1; STE20 RELATED PROLINE ALANINE RICH KINASE; UNCLASSIFIED DRUG; COTRANSPORTER; DIPEPTIDE; HYDROGEN-COUPLED OLIGOPEPTIDE TRANSPORTER PEPT2; PAS DOMAIN KINASES; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; INTESTINE EPITHELIUM; MICHAELIS MENTEN KINETICS; MOUSE; NONHUMAN; OOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REGULATORY MECHANISM; VOLTAGE CLAMP TECHNIQUE; XENOPUS LAEVIS; ANIMAL; GENETICS; INTESTINE; LUMINESCENCE; METABOLISM; PATCH CLAMP TECHNIQUE; PHYSIOLOGY; RABBIT; TRANSGENIC MOUSE;

ANIMALS; DIPEPTIDES; INTESTINES; LUMINESCENCE; MICE; MICE, TRANSGENIC; OOCYTES; PATCH-CLAMP TECHNIQUES; PROTEIN-SERINE-THREONINE KINASES; RABBITS; SYMPORTERS; XENOPUS LAEVIS;

EID: 84910656974     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000368451     Document Type: Article

References (59)

1. Inoue M, Terada T, Okuda M, Inui K: Regulation of human peptide transporter 1 (PEPT1) in gastric cancer cells by anticancer drugs. Cancer Lett 2005;230:72-80.
2. Rubio-Aliaga I, Daniel H: Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 2008;38:1022-1042.
3. Ingersoll SA, Ayyadurai S, Charania MA, Laroui H, Yan Y, Merlin D: The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2012;302:G484-G492.
4. Smith DE, Clemencon B, Hediger MA: Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol Aspects Med 2013;34:323-336.
5. Nielsen CU, Brodin B: Di/tri-peptide transporters as drug delivery targets: regulation of transport under physiological and patho-physiological conditions. Curr Drug Targets 2003;4:373-388.
6. Yarandi SS, Hebbar G, Sauer CG, Cole CR, Ziegler TR: Diverse roles of leptin in the gastrointestinal tract: modulation of motility, absorption, growth, and inflammation. Nutrition 2011;27:269-275.
7. Alteheld B, Evans ME, Gu LH, Ganapathy V, Leibach FH, Jones DP, Ziegler TR: Alanylglutamine dipeptide and growth hormone maintain PepT1-mediated transport in oxidatively stressed Caco-2 cells. J Nutr 2005;135:19-26.
8. Rexhepaj R, Rotte A, Pasham V, Gu S, Kempe DS, Lang F: PI3 kinase and PDK1 in the regulation of the electrogenic intestinal dipeptide transport. Cell Physiol Biochem 2010;25:715-722.
9. Boehmer C, Palmada M, Klaus F, Jeyaraj S, Lindner R, Laufer J, Daniel H, Lang F: The peptide transporter PEPT2 is targeted by the protein kinase SGK1 and the scaffold protein NHERF2. Cell Physiol Biochem 2008;22:705-714.
10. Pieri M, Christian HC, Wilkins RJ, Boyd CA, Meredith D: The apical (hPepT1) and basolateral peptide transport systems of Caco-2 cells are regulated by AMP-activated protein kinase. Am J Physiol Gastrointest Liver Physiol 2010;299:G136-G143.
11. Rafiqi FH, Zuber AM, Glover M, Richardson C, Fleming S, Jovanovic S, Jovanovic A, O'Shaughnessy KM, Alessi DR: Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol Med 2010;2:63-75.
12. Castaneda-Bueno M, Gamba G: SPAKling insight into blood pressure regulation. EMBO Mol Med 2010;2:39-41.
13. Yang SS, Lo YF, Wu CC, Lin SW, Yeh CJ, Chu P, Sytwu HK, Uchida S, Sasaki S, Lin SH: SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction. J Am Soc Nephrol 2010;21:1868-1877.
14. Vitari AC, Deak M, Morrice NA, Alessi DR: The WNK1 and WNK4 protein kinases that are mutated in Gordon's hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases. Biochem J 2005;391:17-24.
15. Vitari AC, Thastrup J, Rafiqi FH, Deak M, Morrice NA, Karlsson HK, Alessi DR: Functional interactions of the SPAK/OSR1 kinases with their upstream activator WNK1 and downstream substrate NKCC1. Biochem J 2006;397:223-231.
16. Glover M, Zuber AM, O'Shaughnessy KM: Hypertension, dietary salt intake, and the role of the thiazidesensitive sodium chloride transporter NCCT. Cardiovasc Ther 2011;29:68-76.
17. O'Reilly M, Marshall E, Speirs HJ, Brown RW: WNK1, a gene within a novel blood pressure control pathway, tissue-specifically generates radically different isoforms with and without a kinase domain. J Am Soc Nephrol 2003;14:2447-2456.
18. Kahle KT, Rinehart J, Lifton RP: Phosphoregulation of the Na-K-2Cl and K-Cl cotransporters by the WNK kinases. Biochim Biophys Acta 2010;1802:1150-1158.
19. Flatman PW: Cotransporters, WNKs and hypertension: an update. Curr Opin Nephrol Hypertens 2008;17:186-192.
20. Furgeson SB, Linas S: Mechanisms of type I and type II pseudohypoaldosteronism. J Am Soc Nephrol 2010;21:1842-1845.
21. Uchida S: Pathophysiological roles of WNK kinases in the kidney. Pflugers Arch 2010;460:695-702.
22. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, Lifton RP: Human hypertension caused by mutations in WNK kinases. Science 2001;293:1107-1112.
23. Delpire E, Gagnon KB: SPAK and OSR1, key kinases involved in the regulation of chloride transport. Acta Physiol (Oxf) 2006;187:103-113.
24. Delpire E, Gagnon KB: SPAK and OSR1: STE20 kinases involved in the regulation of ion homoeostasis and volume control in mammalian cells. Biochem J 2008;409:321-331.
25. Gimenez I: Molecular mechanisms and regulation of furosemide-sensitive Na-K-Cl cotransporters. Curr Opin Nephrol Hypertens 2006;15:517-523.
26. Richardson C, Sakamoto K, de los HP, Deak M, Campbell DG, Prescott AR, Alessi DR: Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and -independent pathways. J Cell Sci 2011;124:789-800.
27. Gagnon KB, Delpire E: On the substrate recognition and negative regulation of SPAK, a kinase modulating Na+-K+-2Cl- cotransport activity. Am J Physiol Cell Physiol 2010;299:C614-C620.
28. Glover M, O'Shaughnessy KM: SPAK and WNK kinases: a new target for blood pressure treatment? Curr Opin Nephrol Hypertens 2011;20:16-22.
29. Lin SH, Yu IS, Jiang ST, Lin SW, Chu P, Chen A, Sytwu HK, Sohara E, Uchida S, Sasaki S, Yang SS: Impaired phosphorylation of Na(+)-K(+)-2Cl(-) cotransporter by oxidative stress-responsive kinase-1 deficiency manifests hypotension and Bartter-like syndrome. Proc Natl Acad Sci USA 2011;108:17538-17543.
30. Mercier-Zuber A, O'Shaughnessy KM: Role of SPAK and OSR1 signalling in the regulation of NaCl cotransporters. Curr Opin Nephrol Hypertens 2011;20:534-540.
31. Richardson C, Alessi DR: The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway. J Cell Sci 2008;121:3293-3304.
32. Villa F, Deak M, Alessi DR, van Aalten DM: Structure of the OSR1 kinase, a hypertension drug target. Proteins 2008;73:1082-1087.
33. Huang CL, Yang SS, Lin SH: Mechanism of regulation of renal ion transport by WNK kinases. Curr Opin Nephrol Hypertens 2008;17:519-525.
34. Achard JM, Disse-Nicodeme S, Fiquet-Kempf B, Jeunemaitre X: Phenotypic and genetic heterogeneity of familial hyperkalaemic hypertension (Gordon syndrome). Clin Exp Pharmacol Physiol 2001;28:1048-1052.
35. Capasso G, Cantone A, Evangelista C, Zacchia M, Trepiccione F, Acone D, Rizzo M: Channels, carriers, and pumps in the pathogenesis of sodium-sensitive hypertension. Semin Nephrol 2005;25:419-424.
36. Hoffmann EK, Schettino T, Marshall WS: The role of volume-sensitive ion transport systems in regulation of epithelial transport. Comp Biochem Physiol A Mol Integr Physiol 2007;148:29-43.
37. Pathare G, Foller M, Daryadel A, Mutig K, Bogatikov E, Fajol A, Almilaji A, Michael D, Stange G, Voelkl J, Wagner CA, Bachmann S, Lang F: OSR1-sensitive renal tubular phosphate reabsorption. Kidney Blood Press Res 2012;36:149-161.
38. Pathare G, Foller M, Michael D, Walker B, Hierlmeier M, Mannheim JG, Pichler BJ, Lang F: Enhanced FGF23 serum concentrations and phosphaturia in gene targeted mice expressing WNK-resistant SPAK. Kidney Blood Press Res 2012;36:355-364.
39. Pasham V, Rotte A, Yang W, Zelenak C, Bhandaru M, Foller M, Lang F: OSR1-sensitive regulation of Na+/H+ exchanger activity in dendritic cells. Am J Physiol Cell Physiol 2012;303:C416-426.
40. Hosseinzadeh Z, Dong L, Bhavsar SK, Warsi J, Almilaji A, Lang F: Upregulation of peptide transporters PEPT1 and PEPT2 by Janus kinase JAK2. Cell Physiol Biochem 2013;31:673-682.
41. Dermaku-Sopjani M, Almilaji A, Pakladok T, Munoz C, Hosseinzadeh Z, Blecua M, Sopjani M, Lang F: Downregulation of the Na-coupled phosphate transporter NaPi-IIa by AMP-activated protein kinase. Kidney Blood Press Res 2013;37:547-556.
42. Alesutan I, Sopjani M, Dermaku-Sopjani M, Munoz C, Voelkl J, Lang F: Upregulation of Na-coupled glucose transporter SGLT1 by Tau tubulin kinase 2. Cell Physiol Biochem 2012;30:458-465.
43. Henrion U, Zumhagen S, Steinke K, Strutz-Seebohm N, Stallmeyer B, Lang F, Schulze-Bahr E, Seebohm G: Overlapping cardiac phenotype associated with a familial mutation in the voltage sensor of the KCNQ1 channel. Cell Physiol Biochem 2012;29:809-818.
44. Hosseinzadeh Z, Bhavsar SK, Lang F: Downregulation of ClC-2 by JAK2. Cell Physiol Biochem 2012;29:737-742.
45. Bogatikov E, Munoz C, Pakladok T, Alesutan I, Shojaiefard M, Seebohm G, Foller M, Palmada M, Bohmer C, Broer S, Lang F: Up-regulation of amino acid transporter SLC6A19 activity and surface protein abundance by PKB/Akt and PIKfyve. Cell Physiol Biochem 2012;30:1538-1546.
46. Hosseinzadeh Z, Bhavsar SK, Lang F: Down-regulation of the myoinositol transporter SMIT by JAK2. Cell Physiol Biochem 2012;30:1473-1480.
47. Mia S, Munoz C, Pakladok T, Siraskar G, Voelkl J, Alesutan I, Lang F: Downregulation of Kv1.5 K channels by the AMP-activated protein kinase. Cell Physiol Biochem 2012;30:1039-1050.
48. Pakladok T, Almilaji A, Munoz C, Alesutan I, Lang F: PIKfyve sensitivity of hERG channels. Cell Physiol Biochem 2013;31:785-794.
49. Meredith D: Review. The mammalian proton-coupled peptide cotransporter PepT1: sitting on the transporter-channel fence? Philos Trans R Soc Lond B Biol Sci 2009;364:203-207.
50. Foley DW, Rajamanickam J, Bailey PD, Meredith D: Bioavailability through PepT1: the role of computer modelling in intelligent drug design. Curr Comput Aided Drug Des 2010;6:68-78.
51. Yan Y, Merlin D: Ste20-related proline/alanine-rich kinase: a novel regulator of intestinal inflammation. World J Gastroenterol 2008;14:6115-6121.
52. Newstead S: Towards a structural understanding of drug and peptide transport within the proton-dependent oligopeptide transporter (POT) family. Biochem Soc Trans 2011;39:1353-1358.
53. Brandsch M: Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opin Drug Metab Toxicol 2009;5:887-905.
54. Kamal MA, Keep RF, Smith DE: Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity. Drug Metab Pharmacokinet 2008;23:236-242.
55. Nakamura T, Yamamori M, Sakaeda T: Pharmacogenetics of intestinal absorption. Curr Drug Deliv 2008;5:153-169.
56. Mitsuoka K, Kato Y, Miyoshi S, Murakami Y, Hiraiwa M, Kubo Y, Nishimura S, Tsuji A: Inhibition of oligopeptide transporter suppress growth of human pancreatic cancer cells. Eur J Pharm Sci 2010;40:202-208.
57. Tsume Y, Hilfinger JM, Amidon GL: Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm 2008;5:717-727.
58. Gonzalez DE, Covitz KM, Sadee W, Mrsny RJ: An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res 1998;58:519-525.
59. Tai W, Chen Z, Cheng K: Expression Profile and Functional Activity of Peptide Transporters in Prostate Cancer Cells. Mol Pharm 2013;10:477-487.